Featured Research

from universities, journals, and other organizations

Pancreatic Cancer Vaccine Found Safe In Early Study

Date:
December 29, 2000
Source:
Johns Hopkins Medical Institutions
Summary:
Hopkins researchers say early tests of a pancreatic cancer vaccine show it is safe and successful in reaching immune system cells. The vaccine, tested on 14 patients, uses lab-grown pancreatic cancer cells genetically-modified with the immune-boosting gene GM-CSF.

Hopkins researchers say early tests of a pancreatic cancer vaccine show it is safe and successful in reaching immune system cells. A report on the findings is published in the Journal of Clinical Oncology, Vol. 19, No. 1, (January) 2001.

The vaccine, tested on 14 patients, uses lab-grown pancreatic cancer cells genetically-modified with the immune-boosting gene GM-CSF.

After surgery to remove the pancreatic cancers, patients received varying doses of the vaccine. Twelve of the 14 then underwent radiation and chemotherapy following the initial vaccination. Six patients received up to three additional monthly vaccinations.

Researchers found that several parts of the immune system were activated in three patients who got the highest doses. These patients remain disease-free more than 30 months after diagnosis. The other 11 patients showed no significant immune response. Side effects included only local skin reactions and redness and itchiness at the vaccine site for several days.

"This study was just a first step, but we are encouraged to find that it is safe and initiates an immune response in certain doses," says Elizabeth Jaffee, M.D., associate professor of oncology and lead author of the study.

To create the vaccine, researchers inserted the GM-CSF gene into pancreatic cancer cell lines. GM-CSF, the most potent gene known to activate the immune system, attracts immune cells to the site of the tumor vaccine where they recognize antigens found on the cancer cell surface. These antigens then serve as red flags, causing the immune system to seek out and destroy cancer cells elsewhere in the patient.

"Genetically-engineered vaccines like this could be used to ‘mop up' microscopic cancer cells left behind following surgery, chemotherapy, and radiation," says Jaffee. "We need to find the best combination of these treatments that will afford patients the best chance for survival."

Researchers caution that further studies are necessary to evaluate the vaccine's effectiveness. The second phase of trials at Hopkins could begin in early summer 2001.

Pancreatic cancer strikes more than 27,000 people and claims the lives of an additional 28,000 each year. Less than 5 percent of patients survive beyond five years.

This study was funded by the National Cancer Institute (NCI), the Lustgarden Foundation, and the Meyer and Powell families.

In addition to Jaffee, other participants in this study include Ralph H. Hruban, Barbara Biedrzycki, Daniel Laheru, Karen Schepers, Patricia R. Sauter, Marti Goemann, Joanne Coleman from Hopkins, Louise Grochow from NCI, Ross C. Donehower, Keith D. Lillemoe, Seamus O'Reilly, Ross A. Abrams, Drew M. Pardoll, John L. Cameron, and Charles J. Yeo from Hopkins.

Under a licensing agreement between the Johns Hopkins University and Cell Genesys, Dr. Jaffee and Dr. Pardoll are entitled to a share of royalty received by the University on sales of technology used in the study described in this press release. This arrangement is being managed by the University in accordance with its conflict of interest policies.

Related Web Sites:

Johns Hopkins Oncology Center: http://www.hopkinscancercenter.org

Johns Hopkins Pancreatic Cancer Service: http://www.hopkinscancercenter.org/programs/pancreatic.cfm


Story Source:

The above story is based on materials provided by Johns Hopkins Medical Institutions. Note: Materials may be edited for content and length.


Cite This Page:

Johns Hopkins Medical Institutions. "Pancreatic Cancer Vaccine Found Safe In Early Study." ScienceDaily. ScienceDaily, 29 December 2000. <www.sciencedaily.com/releases/2000/12/001229084753.htm>.
Johns Hopkins Medical Institutions. (2000, December 29). Pancreatic Cancer Vaccine Found Safe In Early Study. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2000/12/001229084753.htm
Johns Hopkins Medical Institutions. "Pancreatic Cancer Vaccine Found Safe In Early Study." ScienceDaily. www.sciencedaily.com/releases/2000/12/001229084753.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins